Receptor gene for peptide cancer antigen-specific T cell

Patent metadata

Field	Value
Publication number	US-9803246-B2
Application number	US-201214129695-A
Country	US
Kind code	B2
Filing date	Jun 20, 2012
Priority date	Jun 28, 2011
Publication date	Oct 31, 2017
Grant date	Oct 31, 2017

Abstract

The invention provides the nucleotide sequence and amino acid sequence of the CDR3 domain of the T cell receptor (TCR) gene of a WT1-specific cytotoxic T cell (CTL) against WT1 protein. Also provided are a method for testing for and treating cancer using the nucleotide sequence and amino acid sequence, and a chip, primer set, kit, and device for testing for cancer comprising the nucleotide sequence and amino acid sequence.

First claim

The invention claimed is:

1. A synthesized cDNA, comprising:
(1) a first nucleotide sequence encoding a complementarity determining region 3 (CDR3) of a Vβ chain of a T-cell receptor (TCR) of a WTI-specific HLA-A*0201-positive cytotoxic T-cell (CTL), wherein the CDR3 confers diversity and specificity of WT1-antigen recognition of the CTL, or
(2) a second nucleotide sequence that is complementary to the first nucleotide sequence,
wherein the cDNA is obtained by reverse transcription of RNA of an HLA-A*0201-WT1 126-134 tetramer + CD3 + CD8 + cell.

2. The cDNA according to claim 1 , wherein the cDNA consists of:
(1) the first nucleotide sequence, or
(2) the second nucleotide sequence.

3. The cDNA according to claim 1 , wherein the cDNA is labelled.

4. The cDNA according to claim 1 , comprising (1) the first nucleotide sequence.

5. The cDNA according to claim 1 , comprising (2) the second nucleotide sequence.

6. A chip comprising a plurality of different isolated polynucleotides immobilized on the chip, each of the plurality of different isolated polynucleotides immobilized on the chip comprising:
a cDNA sequence encoding an entire amino acid sequence of a complementarity determining region 3 (CDR3) of a Vβ chain of a T-cell receptor (TCR) of a WT1-specific HLA-A*0201-positive cytotoxic T-cell (CTL);
an RNA sequence of a nucleotide that is complementary to the full length of the cDNA sequence; or
a DNA sequence of the nucleotide that is complementary to the full length of the cDNA sequence.

7. The chip according to claim 6 , wherein the isolated polynucleotides further comprise a label.

8. The chip according to claim 1 , wherein the label is selected from the group consisting of a fluorescent label, a radioactive label, an enzyme label, and a chromophore label.

9. The chip according to claim 7 , further comprising a labeled or unlabeled sample placed on the chip.

10. The chip according to claim 6 , further comprising a labeled sample placed on the chip.

Assignees

• Sugiyama Haruo
• Int Inst Cancer Immunology Inc

Inventors

• Sugiyama Haruo

Classifications

• G01N33/575

  for cancer · CPC title

• C07K2317/34

  Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title

• C12Q1/6881

  for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes · CPC title

• G01N33/56977

  HLA or MHC typing · CPC title

• C07K16/30

  from tumour cells · CPC title